Kinomica
Kinomica is applying phosphoproteomics to cancer diagnostics and precision medicine with the goal of helping clinicians select the right therapy for the right patient at the right time. They have developed KScan®, a phosphoproteomic diagnostic platform, to realize the full potential of precision medicine. The company focuses on questions such as identifying the best drugs for individual patients, finding alternative drugs for non-responders or relapsed patients, and developing better drugs through phosphoproteomics. Their technologies include liquid chromatography mass spectrometry, spectral peak identification and quantification, ML-derived predictive assays, and algorithms for measuring kinase activity. They are developing multi-drug diagnostics for diseases like hepatocellular carcinoma and acute myeloid leukemia.
Industries
Nr. of Employees
small (1-50)
Patents
Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy
US-12282021-B2
View Details
Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy
US-12282021-B2
View DetailsProducts
Phosphoproteomic diagnostic platform
A mass spectrometry–based diagnostic platform that measures phosphorylation and signaling activity to support selection of therapies for individual patients.
KScan
A phosphoproteomic diagnostic platform developed to help clinicians select the right therapy and realize the full potential of precision medicine.
Kinomica Phosphoproteomic Technology Suite
An integrated suite of proprietary phosphoproteomic technologies covering liquid chromatography mass spectrometry, spectral peak identification, ML-derived predictive assays, and kinase activity measuring algorithms.
Phosphoproteomic diagnostic platform
A mass spectrometry–based diagnostic platform that measures phosphorylation and signaling activity to support selection of therapies for individual patients.
KScan
A phosphoproteomic diagnostic platform developed to help clinicians select the right therapy and realize the full potential of precision medicine.
Kinomica Phosphoproteomic Technology Suite
An integrated suite of proprietary phosphoproteomic technologies covering liquid chromatography mass spectrometry, spectral peak identification, ML-derived predictive assays, and kinase activity measuring algorithms.
Services
Laboratory-based profiling service that measures phosphorylation and ranks enzyme/kinase activity in tissue samples to support biomarker discovery and drug-response prediction.
Data processing and interpretation service for SWATH-MS, DDA and other LC-MS/MS datasets, including spectral identification, quantification and protein identification workflows.
Development of machine learning–derived assays from phosphoproteomic data to predict patient response to specific therapies or combinations.
Laboratory-based profiling service that measures phosphorylation and ranks enzyme/kinase activity in tissue samples to support biomarker discovery and drug-response prediction.
Data processing and interpretation service for SWATH-MS, DDA and other LC-MS/MS datasets, including spectral identification, quantification and protein identification workflows.
Development of machine learning–derived assays from phosphoproteomic data to predict patient response to specific therapies or combinations.
Expertise Areas
- Phosphoproteomic biomarker discovery
- Clinical diagnostic development for oncology
- Mass spectrometry proteomics (LC-MS/MS, SWATH, DDA)
- Proteomics bioinformatics and software
Key Technologies
- Phosphoproteomics
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- SWATH-MS
- Data-dependent acquisition (DDA)
News & Updates
Kinomica showcased their research on phosphoproteomic signatures for AML response to treatment at the ASCO conference.
Kinomica was recognized by Bruntwood SciTech for their innovative cell signalling profiling service KScan® and its ability to predict drug response more accurately than genomic data.
Kinomica was highlighted for their energy, attention-grabbing technology, and a higher proportion of women in senior management than other biotech companies.
Kinomica showcased their research on phosphoproteomic signatures for AML response to treatment at the ASCO conference.
Kinomica was recognized by Bruntwood SciTech for their innovative cell signalling profiling service KScan® and its ability to predict drug response more accurately than genomic data.
Kinomica was highlighted for their energy, attention-grabbing technology, and a higher proportion of women in senior management than other biotech companies.